Ochola-Oyier Lynette Isabella, Okombo John, Mwai Leah, Kiara Steven M, Pole Lewa, Tetteh Kevin K A, Nzila Alexis, Marsh Kevin
Kenya Medical Research Institute/Wellcome Trust Collaborative Research Program, Kilifi, Kenya
Kenya Medical Research Institute/Wellcome Trust Collaborative Research Program, Kilifi, Kenya.
Antimicrob Agents Chemother. 2015 Mar;59(3):1770-5. doi: 10.1128/AAC.03522-14. Epub 2014 Dec 22.
The mechanisms of drug resistance development in the Plasmodium falciparum parasite to lumefantrine (LUM), commonly used in combination with artemisinin, are still unclear. We assessed the polymorphisms of Pfmspdbl2 for associations with LUM activity in a Kenyan population. MSPDBL2 codon 591S was associated with reduced susceptibility to LUM (P = 0.04). The high frequency of Pfmspdbl2 codon 591S in Kenya may be driven by the widespread use of lumefantrine in artemisinin combination therapy (Coartem).
恶性疟原虫对通常与青蒿素联合使用的卤泛群(LUM)产生耐药性的机制仍不清楚。我们评估了肯尼亚人群中Pfmspdbl2的多态性与卤泛群活性的相关性。MSPDBL2密码子591S与对卤泛群的敏感性降低相关(P = 0.04)。肯尼亚Pfmspdbl2密码子591S的高频率可能是由于卤泛群在青蒿素联合疗法(科泰复)中的广泛使用所致。